anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
GLYRX®-PF is a synthetic anticholinergic agent. It is intended for intramuscular or intravenous administration. Each 1 mL of GLYRX®-PF contains 0.2 mg of glycopyrrolate, water for injection, sodium chloride as a tonicity agent, and hydrochloric acid or sodium hydroxide as pH adjusters. GLYRX®-PF is preservative free.

Glycopyrrolate is a quaternary ammonium salt with the following chemical name: (RS)-[3-(SR)-Hydroxy-1,1-dimethylpyrrolidinium bromide] α-cyclopentylmandelate. The molecular formula is C19H28BrNO3 and the molecular weight is 398.34. Glycopyrrolate structural formula is as follows:

Glycopyrrolate occurs as a white, odorless, crystalline powder. It is soluble in water and alcohol, and practically insoluble in chloroform and ether. It is completely ionized at physiological pH values. GLYRX®-PF is a clear, colorless, sterile liquid with a pH of 2.0 – 3.0. The partition coefficient of Glycopyrrolate in n-octanol/water system is 0.304 (log10 P = -1.52) at ambient room temperature (24°C).
Biologically active substance with standardizable hormonal activity, containing in a physiological medium at least one histone, particularly at least one histone H2 or an active area of said histone with immune system immunostimulating and/or endocrinological properties. Utilization of histones and/or segments of histones for producing such a preparation for medical purposes. Said histones may be extracted from biological starting materials, for example calf thymus. Since H2A and H2B histones of oxen and humans are identical, ox histones may also be used for such a preparation for human medical purposes. The preparation according to the present invention may also contain only the variable evolution segments or part of at least one H2 histone. The invention is based on the fact that the biologically active area of an immunostimulating or endocrinologically active histone is located in the variable evolution histone segment. The preparation according to the present invention may be used in immunotherapy.
At the commencement of surgery a bolus of Hartmann's balanced salt crystalloid 10 ml/kg followed by 8 ml/kg/h will be administered until the end of surgery. A maintenance infusion will then continue at 1.5 ml/kg/h, for at least 24 hours, but this can be reduced postoperatively if there is evidence of fluid overload and no hypotension, and increased if there is evidence of hypovolaemia or hypotension. Alternative fluid types (crystalloid, dextrose, colloid) and electrolyte supplements will be allowed postoperatively in order to account for local preferences and patient biochemistry, for which we will collect data.
The present disclosure relates to a control method and a medical system. A method for controlling a medical system includes the following steps. An initial symptom is received. A neural network model is utilized to select symptom query actions. A symptom response to the symptom asking action is received. And selecting a medical detection action according to the initial symptom and the symptom response by using a neural network model. A test result for the medical test action is received. And selecting a result prediction action according to the initial symptom, the symptom response and the detection result by using a neural network model.
The calf stretching treatment is a technique that is commonly used in sports and rehabilitation. You will be asked to place your foot on a slant board located next to a wall with your heel positioned below your toes on the slant board. You will be asked to lean towards the wall until you feel tension in your calf muscles that feels like a good stretch. You will perform 2 sets of 3 stretches that are held for 30 seconds each. Between each stretch, you will rest for 10 seconds. Between each set, you will rest for 1 minute.
FIELD: medicine, immunology. SUBSTANCE: patient is prescribed pyrogenal in 2-3 days simultaneously with preparations of metronidazole group and/or quinolones daily for 3-6 months depending on disease severity degree. Then an interval of 5-7 days is needed followed by rocefin application together with autoblood every other day for a course of 2-6 weeks. After the second 7-8-day-long interval pyrogenal is again prescribed according to previous scheme along with daily intake of tetracyclines for a course of 2-3 weeks. Moreover, patients are prescribed for symptomatic treatment. EFFECT: higher efficiency of therapy, decreased number of relapses.
The invention relates to health preserving honey wine. The fermentation method of flavor liquor of the health preserving honey wine comprises the following steps: boiling 3 parts of loquat powder, 3 parts of Chinese-date powder, 1-2 parts of ginseng powder and 200 parts of water; cooling to room temperature; and putting 95 parts of domesticated cauliflower honey, 5 parts of wild honey and 30 parts of red rice in a sealed wine jar for fermenting for 30-40 months in the open air. A blending method comprises the following steps: seasoning 5% flavor liquor and 95% basic liquor; and blending until the alcohol content is 12%. As many food materials and medicinal materials are added and the fermentation time is long, the brewed honey wine is rich in beneficial bacteria. In the long fermentation process, nutritional matters and cultures interact to form richer vitamins and other matter components which are easily absorbed by a human body, so that the health preserving honey wine is high in nutritional value. The health preserving honey wine is deep in color and luster. The seasoned liquor is red and extremely high in brightness. The health preserving honey wine has the effects of resisting senescence, lubricating intestinal tract, promoting digestion function and maintaining beauty and keeping young after being drunk.
BACKGROUND: Metatarsalgia is a common diagnosis for patients with forefoot pain. Many have proposed metatarsal fat pad atrophy is a cause of metatarsalgia and therefore have suggested fat grafting instead of distal metatarsal osteotomies to treat metatarsalgia. For fat grafting to be a viable treatment, fat pad atrophy should correlate with metatarsalgia. This study looked to determine the relationship between metatarsal fat pad thickness and metatarsalgia and the correlation between metatarsal fat pad thickness and patient-reported outcomes.
METHODS: We conducted a retrospective review of patients with metatarsalgia and those with foot or ankle osteoarthritis who had a nonweightbearing MRI performed between February 1, 2021, and March 1, 2023. Data collected included demographics, PROMIS scores, metatarsal fat pad thickness in the second and third rays of the affected foot, and thinnest area on coronal section, measured on MRI. Student t test was used to compare continuous variables, whereas the χ2 test was used to compare categorical variables. Multivariable linear regression models were used to control for potential confounding factors.
RESULTS: A total of 112 patients were included in this study. Patients with metatarsalgia were significantly more likely to have a lower body mass index (29.3 vs 32.0, P = .03) than patients with osteoarthritis, but this finding was not present when controlling for confounding variables. We found no significant difference in fat pad thickness between patients with metatarsalgia vs patients with foot or ankle osteoarthritis (P = .43). We found no correlation between metatarsal fat pad thickness and pain interference (P = .59), physical function (P = .64), or mobility (P = .94) PROMIS scores.
CONCLUSION: In this retrospective comparative study of a relatively small cohort we found no significant difference in metatarsal fat pad thickness for patients with metatarsalgia vs patients with foot and ankle osteoarthritis based on nonweightbearing MRI, and no association between metatarsal fat pad thickness and patient-reported outcomes.
LEVEL OF EVIDENCE: Level III, case control study.
Exercise group will have 6 visit and 8 phone call. Subject will have to do prescribed exercice for 1h, 3 times a week for 12 weeks.
Small molecules are being explored intensively for their applications as therapeutic molecules in the management of metabolic and neurological disorders. The natural small molecules can inhibit protein aggregation and underlying cellular pathogenesis of neurodegenerative diseases involving multi-factorial mechanisms of action. Certain natural small molecular inhibitors of pathogenic protein aggregation are highly efficient and have shown promising therapeutic potential. In the present study, Shikonin (SHK), a natural plant-based naphthoquinone has been investigated for its aggregation inhibition activity against α-synuclein (α-syn) and the neuroprotective potential in Caenorhabditis elegans (C. elegans). SHK significantly inhibited aggregation of α-syn at sub-stochiometric concentrations, delayed the linear lag phase and growth kinetics of seeded and unseeded α-syn aggregation. The binding of SHK to the C-terminus of α-syn maintained α-helical and disordered secondary structures with reduced beta-sheet content and complexity of aggregates. Further, in C. elegans transgenic PD models, SHK significantly reduced α-syn aggregation, improved locomotor activity and prevented dopaminergic (DA) neuronal degeneration, indicating the neuroprotective role of SHK. The present study highlights the potential of natural small molecules in the prevention of protein aggregation that may further be explored for their therapeutic efficacy in the management of protein aggregation and neurodegenerative diseases.
Participants with RMHNSCC who are under palliative treatment will be included in this group. Drug testing on PDX per Investigator's choice (upto 4): PDX will be developed and upto four Chemotherapeutics (that are funded in Ontario) will be tested on the PDX. Chemotherapeutics will be selected at the discretion of the treating Medical Oncologists. Result of the drug testing will be provided to the responsible physician and can be utilized in patient care.
The present invention relates to a Yanminling throat sprayer and a preparing technology thereof. The Yanminling throat sprayer is characterized in that 14.5 to 15.5kg of mahonia, 14.5 to 15.5kg of rhizoma, 9.5 to 10.5kg of platycodon root, 4.5 to 5.5kg of vietnamese sophora root, 9.5 to 10.5kg of mint and 0.45 to 0.55kg of sodium borate are required for manufacturing 30kg of throat sprayers. The mint is distilled, mahonia, rhizoma, platycodon root and vietnamese sophora root are washed cleanly, and are added with dregs of decoction of mint for decocting twice by adding water, and each time is one hour. The decoction liquid is concentrated to a sugar syrup shape, and is added with ethanol of 65% with the quantity of two times of the concentration liquid. The concentration liquid is left to stand for 12 hours and filtered, filtrate is decompressed, and ethanol is recovered. The filtrate is diluted by adding water for injection, stood and filtered. The mint distillate and the filtrate are combined, sodium borate is added for dissolution, and water for injection is added; the present invention is obtained after filtration.
Disclosed are methods for identification of agents that modulate cell attachment, cell migration and cell viability. Cancer and primary cells adhered to a matrix are treated with agent(s) that modulate ActRII signaling and cell adhesion. Agents are tested that modulate cell adhesion, detachment, invasion and viability. Agents that modulate the expression, phosphorylation, function and translocation of ActRII signaling pathway members also can predict agents that modulate cell adhesion, detachment, invasion and viability. The methods have utility in tissue engineering as well as identifying agents that prevent cancer cell metastasis, wound dehiscence, aortic dissection and aid retina attachment and skin replacement and fertility. Examples of tissue engineering include techniques that allow for the generation of biological substitutes that restore, maintain, or improve tissue function or a whole organ.
Embodiments of the present disclosure provides a personal monitoring system to be worn by a first user. The system includes an accelerometer for continuously detecting physical movements comprising falls of the first user. The system further includes at least one photoplethysmography (PPG) sensor for continuously measuring biometric data of the first user. The system further includes a live messaging module for sending at least one notification message to one or more second users associated with the first user through a network when at least one event associated with the first user occurs. The notification message informs the second users about the event so that at least one second user takes an action to ensure safety of the first user. The system further includes a learning module in communication with the at least one PPG sensor.
Treatments capable of remyelination are a major unmet need for multiple sclerosis and other diseases that involve myelin damage, loss, or dysfunction in the central nervous system (CNS). Chronic demyelination of axons is believed to be injurious to neurons and serves as a major contributor to irreversible cell loss that underlies permanent disability. Available MS treatments are primarily immunosuppressing, without directly addressing or fully preventing axonal degeneration and disability. Clemastine fumarate was identified along with a series of other antimuscarinic medications as a potential remyelinating agent using the micropillar screen (BIMA) developed at UCSF. The screen demonstrated that clemastine promoted the differentiation of the endogenous oligodendrocyte precursor cells (OPCs) into mature myelinating oligodendrocytes. Following in vivo validation, an FDA investigational new drug (IND) exemption was granted to investigate clemastine for the treatment of multiple sclerosis in the context of chronic optic neuropathy. That pilot study was recently completed and is the first randomized control trial documenting efficacy for a putative remyelinating agent for the treatment of MS. The preselected primary efficacy endpoint (visual evoked potential) was met and a strong trend to benefit was seen for the principal secondary endpoint assessing function (low contrast visual acuity). That trial number was 13-11577.

This clinical trial is intended to assess magnetic resonance imaging evidence of remyelination using Clemastine Fumarate in patients with chronic demyelinated lesions. Specifically speaking, the primary objective will assess various multi-parametric MRI sequences on the corpus callosum region, a region that animal models studies identified as a promising candidate for assessing remyelination. The aim was to help define the potential for MRI in measuring remyelination in MS, determine the optimal sequences and location for measuring myelin recovery, and help guide trial design for future remyelinating trials. Finally, the study is designed to assess tolerability and clinical efficacy of Clemastine using outcomes intended to assess for (a) adverse events and (b) recovery of myelin.
Across varied disciplines, the science is clear that early relationships and the quality of early care are central in achieving positive language, cognitive, and social development outcomes for young children and investments made in early childhood pay for themselves. Early childhood education is a critical context for fostering stimulating, responsive, and sensitive caregiving as a substantial number of children under the age of 5 years spend time in childcare settings, with 64% of children aged 3 to 5 years enrolled in non-relative care outside the home. While great efforts are made to improve the children's social emotional well-being in child care environments, less attention has been given to early childhood educators' (encompassing of early childhood teachers') own well-being. Research that has been conducted finds early childhood educators experience high levels of distress, including high levels of depression and burnout. Additionally, previous research finds school age teachers feeling overworked and overstressed show an altered hypothalamus-pituitary-adrenal (HPA) axis and higher levels of teacher burnout is related to elevated cortisol levels in elementary school students.

The current study will test the efficacy of an 8-week compassion and mindfulness based stress reduction program for early childhood educators, as well as characterizing relations from early childhood educator wellbeing to child self-regulation. Teachers will be assigned at the center level to an intervention group or a wait-list comparison condition, with the wait-list group receiving the intervention after the 8-week study. Pre- intervention, teachers in both groups will complete survey measures of their wellbeing, mindfulness, and emotion regulation; emotion regulation tasks; and assessments of stress physiology in the classroom. Teacher-child interactions will be observed and children's self-regulation will be measured. Post-intervention, the same teacher measures will be collected.
The invention provides tissue culture system for primary cells (e.g. normal mammalian primary epithelial progenitors). This system includes: a) a serum-free, chemically defined cell culture media; and, b) methods for isolation and in vitro long-term propagation of primary cells (e.g. primary epithelial cells). Primary cells so isolated and cultured can be kept undifferentiated and proliferate for many weeks (>15 weeks) or population doubling (>35 PD) without senescence, or any detectable genetic alterations. Upon changing media/culture conditions, these cells can be induced to differentiate. 
     The invention also provides methods to transform normal primary cells so cultured into “cancer stem cells.” The genetically defined cancer stem cell tumor model mimics the behavior of the disease closely, e.g., the cells are invasive, hormone responsive and metastatic when injected into mice. The tumor cells express genes that are specific to cancer stem cells identified in patient samples.
FIELD: medicine, neuroimmunology. SUBSTANCE: invention relates to test for antigens associated with cerebrospinal sclerosis. Also, invention relates to generation of hybridomas which produce monoclonal antibodies showing specificity to antigens associated with cerebrospinal sclerosis and to polypeptide also. Invention can be used for diagnosis of cerebrospinal sclerosis, in current clinic observation of patients with cerebrospinal sclerosis in relation to disease development or response to therapy. Invention ensures a possibility for diagnosis and treatment of patients with cerebrospinal sclerosis and other myelinizing diseases. EFFECT: improved method of diagnosis and treatment. 22 cl, 3 tbl, 5 dwg, 13 ex
Canine monocytic ehrlichiosis, caused by Ehrlichia canis is a potentially fatal disease of dogs that requires rapid and accurate diagnosis in order to initiate appropriate therapy leading to a favorable prognosis. In the invention described herein, a new immunoreactive E. canis surface protein gene of 1170-bp was cloned, which encodes a protein with a predicted molecular mass of 42.6 kilodaltons (P43). The P43 gene was not found in E. chaffeensis DNA by Southern blot, and antisera against recombinant P43 (rP43) did not react with E. chaffeensis by IFA. The P43 was located on the surface of E. canis by immunoelectron microscopy. Forty-two dogs exhibiting signs and/or hematologic abnormalities associated with canine ehrlichiosis were tested by IFA and by Western immunoblot. Among the 22 samples that were IFA positive for E. canis, 100 % reacted with the rP43, 96 % with the rP28, and 96 % with the rP140. The specificity of the recombinant proteins compared to IFA was 96 % for rp28, 88 % for P43 and 63 % for P140. Results of this study demonstrate that the rP43 and rP28 are sensitive and reliable serodiagnostic antigens for the diagnosis of Ehrlichia canis infections.
Sarcopenia, a prevalent muscle disease characterized by muscle mass and strength reduction, is associated with impaired skeletal muscle regeneration. However, the influence of the biomechanical properties of sarcopenic skeletal muscle on the efficiency of the myogenic program remains unclear. Herein, we established a mouse model of sarcopenia and observed a reduction in stiffness within the sarcopenic skeletal muscle in vivo. To investigate whether the biomechanical properties of skeletal muscle directly impact the myogenic program, we established an in vitro system to explore the intrinsic mechanism involving matrix stiffness control of myogenic differentiation. Our findings identify the microtubule motor protein, kinesin-1, as a mechano-transduction hub that senses and responds to matrix stiffness, crucial for myogenic differentiation and muscle regeneration. Specifically, kinesin-1 activity is positively regulated by stiff matrices, facilitating its role in transporting mitochondria and enhancing translocation of the glucose transporter GLUT4 to the cell surface for glucose uptake. Conversely, the softer matrices significantly suppress kinesin-1 activity, leading to the accumulation of mitochondria around nuclei and hindering glucose uptake by inhibiting GLUT4 membrane translocation, consequently impairing myogenic differentiation. The insights gained from the in-vitro system highlight the mechano-transduction significance of kinesin-1 motor proteins in myogenic differentiation. Furthermore, our study confirms that enhancing kinesin-1 activity in the sarcopenic mouse model restores satellite cell expansion, myogenic differentiation, and muscle regeneration. Taken together, our findings provide a potential target for improving muscle regeneration in sarcopenia.
PURPOSE:To obtain a carcinogenesis suppressing agent containing dibenzocyclooctadiene type lignanes as active ingredients and having carcinogenesis suppressing activity. CONSTITUTION:The objective carcinogenesis suppressing agent containing a compound, e.g. gomisin A or schizanden, expressed by formula I (R1 to R5 are OCH3 or OH, and R1 and R2, R4 and R5, each forms OCH2O; R8 is H or formula II; R7 is formulas III to VI; R6, R9 and R10 are formula III, formula IV or formula VII, respectively). The compound expressed by formula I is obtained by extracting the above-mentioned compound-containing plant (e.g. Schizandra chinensis Baill) with lower hydrocarbons, removing a solvent and volatile ingredient from the extracted liquid and subjecting the residue to chromatographic treatment. The daily dosage of the compound is preferably 100-450mg in case of oral agent and 2-30mg in case of parenteral agent per adult.
PROBLEM TO BE SOLVED: To obtain a banana pericarp extract which facilitates the decomposition of accumulated fat cells and is useful for inhibiting, preventing, improving or the like obesity by extracting banana pericarps with an acidic aqueous solution. SOLUTION: The objective extract is obtained by extracting a banana, e.g. a banana for eating raw (Musa paradisiacal L. var. sapientum or Musa nana Lour.) or a plantain (a banana for cooking) with an acidic aqueous solution (e.g. a mixture or the like of water and a lower alcohol and/or a polyol) of preferably pH of not more than 6 by means of immersing or immersing under stirring or refluxing followed by filtration. The agent for facilitating lipolysis is obtained by including the above extract. Further, on the above accelerator, the above extract is preferably included in proportions of more than 0.005 wt.% in the dry basis when used as a preparation for external use, 0.01-50 wt.% a day per an adult when used as an oral formation or an ingesta and more than 0.01 ppm in bath water when used as a bathing agent.